Tyler R. Kjorvestad, MD

Clinical Assistant Professor, Psychiatry and Behavioral Sciences
tkjorvestad@kumc.eduProfessional Background
Tyler Kjorvestad, M.D., is an assistant clinical professor in the Department of Psychiatry and Behavioral Sciences and the Department of Internal Medicine at the University of Kansas Medical Center. He also directs the Comprehensive Depression Assessment and Treatment Clinic (CDATC) at The University of Kansas Health System.
Dr. Kjorvestad joined the faculty in 2021 after completing his internal medicine/psychiatry residency at KU Medical Center. He earned his medical degree from the University of Missouri-Kansas City School of Medicine, where he mentored medical students and served as a supplemental instructor for organic chemistry, biochemistry, pathology, and pharmacology.
Dr. Kjorvestad’s research interests include treatment-resistant depression and the use of psychedelic substances in the treatment of psychiatric disorders. He is the founder and editor-in-chief of the Journal of Psychedelic Psychiatry.
Education and Training
- BA, Liberal Arts, University of Missouri-Kansas City, Kansas City, MO
- MD, Medicine, University of Missouri-Kansas City, Kansas City, MO
Professional Affiliations
- KUMC, Compensation Committee, Member, 2022 - Present
- The University of Kansas Health Systems, PIO, Member, 2022 - Present
Research
Overview
Dr. Kjorvestad’s research interests include treatment-resistant depression and the use of psychedelic substances in the treatment of psychiatric disorders. He is the founder and editor-in-chief of the Journal of Psychedelic Psychiatry.
Current Research and Grants
- RECOVER, LivaNova, Site-PI
- IQVIA ITI-007-505 CDA, IQVIA, Site-PI
Publications
- Kjorvestad, Tyler., Ryen. 2019. Beyond Vaping: Psilocybin for the Treatment of Tobacco Use Disorder. The Journal of Psychedelic Psychiatry, 1 (1), 35-39. https://www.journalofpsychedelicpsychiatry.org/psilocybintobaccousedisorder
- Kjorvestad, Tyler., Ryen. 2019. Beyond Vaping: Psilocybin for the Treatment of Tobacco Use Disorder. The Journal of Psychedelic Psychiatry, 1 (1), 35-39. https://www.journalofpsychedelicpsychiatry.org/psilocybintobaccousedisorder
- Kjorvestad, Tyler., Ryen. 2019. Beyond Vaping: Psilocybin for the Treatment of Tobacco Use Disorder. The Journal of Psychedelic Psychiatry, 1 (1), 35-39. https://www.journalofpsychedelicpsychiatry.org/psilocybintobaccousedisorder
- Kjorvestad, Tyler., Ryen. 2020. Selective Use of Ketamine in Patients with Psychotic Disorders. The Journal of Psychedelic Psychiatry, 2 (1), 28-30. https://www.journalofpsychedelicpsychiatry.org/ketamineuseinpsychosis
- Kjorvestad, Tyler ., Ryen. 2020. Medicalization, Decriminalization, Legalization and the Path Forward for Psychedelics. The Journal of Psychedelic Psychiatry, 2 (3), 28-29. https://www.journalofpsychedelicpsychiatry.org/medicalization-editorial